Tiziana Life Sciences Ltd has announced promising topline results from its Phase 2a INFORM-MS trial, which could significantly enhance treatment options for patients suffering from non-active secondary progressive multiple sclerosis (na-SPMS). This update is particularly important as it may reshape the landscape for pharmaceutical preparations aimed at neurodegenerative diseases.

On November 9, 2026, Tiziana Life Sciences, listed on Nasdaq under the ticker TLSA, filed a report detailing the success of its INFORM-MS trial. The trial's dual primary endpoints were achieved, leading to increased interest from both the investment and scientific communities.

Background

Tiziana Life Sciences Ltd, incorporated in the UK, focuses on developing innovative immunomodulation therapies. The company has been actively engaged in clinical trials to advance its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The firm operates within the pharmaceutical preparations sector, specifically under SIC code 2834, which includes companies involved in the research and development of drugs.

What the Filing Says

The November 9 filing reveals that the KOL (Key Opinion Leader) investor call highlighted the consistency between the results of the INFORM-MS trial and the long-term clinical benefits observed in an expanded access program for patients treated with intranasal foralumab. The report states, "INFORM-MS placebo-controlled 12-week findings confirmed longer-term real-world data trends seen in patients treated for up to 3 years in the foralumab expanded access program, including EDSS stabilization and improvement in patients with treatment-refractory na-SPMS progressing via PIRA." This suggests a strong correlation between the trial results and previously observed clinical outcomes.

Impact

The positive results from the INFORM-MS trial may have a significant impact on patients suffering from na-SPMS, a condition that currently has limited treatment options. The findings could also influence the pharmaceutical industry, particularly companies developing therapies for neurodegenerative diseases. Tiziana's advancements may prompt competitors to reevaluate their strategies and research directions.

What's Next

Tiziana Life Sciences has indicated that it will complete the full analysis of the INFORM-MS dataset and discuss next steps with the FDA. This ongoing engagement with regulatory bodies will be crucial for the company as it seeks to bring its innovative treatment options to market.

The filing can be accessed under accession number 0001213900-26-117429.